CA2373178C - Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires - Google Patents
Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires Download PDFInfo
- Publication number
- CA2373178C CA2373178C CA2373178A CA2373178A CA2373178C CA 2373178 C CA2373178 C CA 2373178C CA 2373178 A CA2373178 A CA 2373178A CA 2373178 A CA2373178 A CA 2373178A CA 2373178 C CA2373178 C CA 2373178C
- Authority
- CA
- Canada
- Prior art keywords
- group
- inhibitor
- pharmaceutically acceptable
- carboxylic acid
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Abstract
L'invention concerne un procédé de traitement prophylactique et thérapeutique pour la dégénérescence maculaire liée au vieillissement, ainsi que des procédés de traitement prophylactique et thérapeutique pour les complications exsudatives et atrophiques de ladite dégénérescence. Ces procédés consistent à administrer un inhibiteur de trajet de protéine tyrosine kinase à un animal, du type mammifère, en particulier à un être humain, en quantité suffisante pour les besoins du traitement prophylactique ou thérapeutique de la dégénérescence ou des complications considérées, respectivement. L'invention concerne en outre un procédé de traitement prophylactique et thérapeutique pour la dégénérescence rétinienne, un procédé de traitement prophylactique et thérapeutique pour la dégénérescence choroïdienne, et un procédé de traitement prophylactique et thérapeutique pour l'épaississement de la membrane de Bruch. Ces procédés consistent à administrer un inhibiteur de trajet de protéine tyrosine kinase à un animal, du type mammifère, en particulier à un être humain, en quantité suffisante pour les besoins du traitement prophylactique ou thérapeutique de la dégénérescence maculaire, rétinienne ou choroïdienne, ou bien de l'épaississement de la membrane de Bruch, respectivement. De préférence, cet inhibiteur est de la génistéine ou bien un analogue ou un promédicament correspondant, ou encore un sel pharmaceutiquement acceptable de l'un quelconque de ces produits.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13311299P | 1999-05-07 | 1999-05-07 | |
US60/133,112 | 1999-05-07 | ||
US35044099A | 1999-07-09 | 1999-07-09 | |
US09/350,440 | 1999-07-09 | ||
PCT/US2000/012339 WO2000067738A2 (fr) | 1999-05-07 | 2000-05-05 | Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2373178A1 CA2373178A1 (fr) | 2000-11-16 |
CA2373178C true CA2373178C (fr) | 2013-07-02 |
Family
ID=26831056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2373178A Expired - Fee Related CA2373178C (fr) | 1999-05-07 | 2000-05-05 | Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1178791A2 (fr) |
JP (1) | JP4920134B2 (fr) |
AU (1) | AU774495B2 (fr) |
CA (1) | CA2373178C (fr) |
MX (1) | MXPA01011344A (fr) |
WO (1) | WO2000067738A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2826276A1 (fr) * | 2001-06-20 | 2002-12-27 | Raouf Rekik | Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie |
US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
TW200640443A (en) * | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
US20070149593A1 (en) * | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
JP6930763B2 (ja) * | 2018-01-25 | 2021-09-01 | 国立大学法人大阪大学 | ストレス状態の検出方法、及び、ストレス検出装置 |
CN114931574A (zh) * | 2022-06-14 | 2022-08-23 | 深圳爱尔眼科医院 | 一种铁死亡抑制剂及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09316000A (ja) * | 1996-05-31 | 1997-12-09 | Toagosei Co Ltd | 血管新生抑制用ワクチン |
NZ336035A (en) * | 1996-11-05 | 2002-03-28 | Childrens Medical Center | Angiogenesis inhibitory composition comprising an inhibitory compound and antiinflammatory drug |
AU6553998A (en) * | 1997-03-14 | 1998-09-29 | Regents Of The University Of California, The | Methods for inhibiting bacterial cytotoxicity |
AU744939B2 (en) * | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
EP1061913B1 (fr) * | 1998-03-13 | 2007-06-27 | The Johns Hopkins University School Of Medicine | Traitement de la retinopathie diabetique au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine |
-
2000
- 2000-05-05 MX MXPA01011344A patent/MXPA01011344A/es active IP Right Grant
- 2000-05-05 CA CA2373178A patent/CA2373178C/fr not_active Expired - Fee Related
- 2000-05-05 AU AU49884/00A patent/AU774495B2/en not_active Ceased
- 2000-05-05 EP EP00932108A patent/EP1178791A2/fr not_active Withdrawn
- 2000-05-05 WO PCT/US2000/012339 patent/WO2000067738A2/fr active IP Right Grant
- 2000-05-05 JP JP2000616765A patent/JP4920134B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP4920134B2 (ja) | 2012-04-18 |
AU774495B2 (en) | 2004-07-01 |
JP2002544159A (ja) | 2002-12-24 |
WO2000067738A3 (fr) | 2001-08-23 |
MXPA01011344A (es) | 2004-06-03 |
EP1178791A2 (fr) | 2002-02-13 |
AU4988400A (en) | 2000-11-21 |
CA2373178A1 (fr) | 2000-11-16 |
WO2000067738A2 (fr) | 2000-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6399655B1 (en) | Method for the prophylactic treatment of cataracts | |
US5919813A (en) | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy | |
EP1061913B1 (fr) | Traitement de la retinopathie diabetique au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine | |
US6028099A (en) | Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization | |
US5980929A (en) | Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation | |
Rasmussen et al. | Benzalkonium chloride and glaucoma | |
US11654140B2 (en) | Treatment of ocular inflammatory diseases using laquinimod | |
US20240009168A1 (en) | Compositions for treating dry age-related macular degeneration (amd) | |
CA2373178C (fr) | Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires | |
JP7436067B2 (ja) | ナノ低分子ペプチドfg及びその眼底血管疾患の治療用薬物又は予防用薬物の調製への使用 | |
KR19980063712A (ko) | 망막증의 치료에 유용한 저급 알카노일 l-카르니틴 | |
US11717513B2 (en) | Mirabegron for the treatment of retinal diseases | |
US6852688B2 (en) | Compositions for treating diabetic retinopathy and methods of using same | |
CN113271934B (zh) | 糖尿病性白内障治疗或预防用组合物 | |
US6248759B1 (en) | Method for treatment of light-injured retinal degeneration disease | |
CA2575850A1 (fr) | Traitement de la retinopathie diabetique ou des inflammations oculaires au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine | |
MXPA00008988A (en) | The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation | |
KR20130037994A (ko) | 안지오제닌의 신규 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20160505 |